

# **State of Iowa Department of Corrections Policy and Procedures**

Policy Number: HSP-754

Applicability: DOC

Policy Code: Public Access

Iowa Code Reference: SF 2218/HF 2460

Chapter 6: Health Services

Sub Chapter: Mental Health/Pharmacy

Related DOC Policies: N/A

Administrative Code Reference: N/A

Subject: Naloxone Dispensing for Releasing Incarcerated Individuals/Patients

ACA Standards: N/A

Responsibility: Dr. Jerome Greenfield

Effective Date: November 2020

Authority:

## **1. PURPOSE**

To describe procedures to be utilized by the Iowa Department of Corrections (IDOC) for provision of Naloxone (Narcan) nasal spray to patients being released who have been determined to be at high risk for an opioid-related drug overdose or exposure.

## **2. POLICY**

The Iowa DOC will review those patients scheduled for release to identify those considered at high risk for an opioid-related overdose or exposure once returned to the community. These patients will be offered required training on the use of Naloxone (Narcan) nasal spray in order that a supply may be dispensed to them upon release.

## **3. DEFINITIONS**

- A. Naloxone: A prescription medication indicated for reversal of opioid-related drug exposures or overdoses.
  
- B. Standing Order: The authorization, issued based on Iowa Senate File 2218 and House File 2460, which permits an Iowa pharmacy to distribute Naloxone to certain eligible recipients without a doctor's prescription written for a specific individual, when the pharmacist has complied with the rules of the Iowa Board of Pharmacy.

C. See Iowa DOC Policy **AD-GA-16** for additional definitions.

#### **4. PROCEDURES**

The institutions will follow the following procedures:

- A. All patients with an identified diagnosis of Opioid Use Disorder or that an IDOC provider has identified as being at high risk for possible overdose or exposure to opioids upon release may be considered for participation in the Naloxone (Narcan) nasal spray training program. Patients who have received Medication Assisted Therapy with medications (such as Naltrexone or Buprenorphine/Naloxone) while incarcerated will be considered first.
- B. Patients must consent to participate in the Naloxone (Narcan) program, sign the HSF-754A consent form, and must undergo the IDOC approved training in recognition and response of opioid-related overdose/exposure and the proper administration of Naloxone before the medication can be dispensed. This is required by Iowa Code and the Iowa Board of Pharmacy. An IDOC pharmacist will provide the training during scheduled classes held at each correctional facility.
- C. Patients will be scheduled to receive the training when they are within three months of their designated release date and will be notified of the time the training is to be held at their location.
- D. Once the patient has completed the training, an encounter will be entered in the ICON Medical system by the IDOC Pharmacist that states the training has been completed and contains an order for the Naloxone (Narcan) to be dispensed with the patient's other release medications.
- E. At the time of their release each patient will receive one (1) box of 2 doses of Naloxone (Narcan) nasal spray along with written materials which review the information presented in the Naloxone training. Naloxone orders will be non-refillable and non-transferable.